Advertisement

CEN Case Reports

, Volume 7, Issue 2, pp 217–220 | Cite as

Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome

  • Daisuke Katagiri
  • Fumihiko Hinoshita
Case Report
  • 110 Downloads

Abstract

We encountered a case of gemcitabine (GEM)-induced secondary thrombotic microangiopathy (TMA) with nephrotic syndrome. Advanced pancreatic cancer with liver metastasis had originally been diagnosed. Renal biopsy showed focal reduplication of the glomerular basement membrane, endothelial cell swelling, and narrowed capillary lumens with fragmented erythrocytes and fibrin deposition, compatible with TMA. Regular monitoring of renal function during GEM treatment and discontinuation of treatment if acute kidney injury (AKI) might occur is crucial, because AKI combined with TMA is life-threatening.

Keywords

Thrombotic microangiopathy Gemcitabine AKI Nephrotic syndrome 

Notes

Acknowledgements

We wish to thank Dr. Makoto Tokuhara from the Department of Surgery at the National Center for Global Health and Medicine, Tokyo, Japan, for referring the patient, and Dr. Makoto Mochizuki from the Department of Pathology at Teikyo University Hospital, Tokyo, Japan for his advice regarding the pathology. This study was partly supported by overseas research fellowships (to D.K) from Uehara Memorial Foundation and 46th KANAE grants (to D.K) from the KANAE Foundation for the Promotion of Medical Science.

Compliance with ethical standards

Conflict of interest

Authors have declared that no conflict of interest exists for this work.

Ethical statement

All of the treatment and the examination followed the guideline laid down in the Declaration of Helsinki.

Informed consent

Informed consent for the treatment and the renal biopsy was obtained from the patient.

References

  1. 1.
    Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100:2664–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Lee HW, Chung MJ, Kang H, et al. Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature. Gut Liver. 2014;8:109–12.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yamada Y, Suzuki K, Nobata H, et al. Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud’s phenomenon, positive antinuclear antibodies and hypertensive emergency. Intern Med. 2014;53:445–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164:759–66.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jokiranta TS. HUS and atypical HUS. Blood. 2017;129:2847–56.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Shah N, Rutherford C, Matevosyan K, et al. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol. 2013;163:514–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Kato H, Nangaku M, Hataya H, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:536–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012;91:195–205.CrossRefGoogle Scholar
  9. 9.
    Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17:5858–66.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Green MR. Gemcitabine safety overview. Semin Oncol. 1996;23:32–5.PubMedGoogle Scholar
  11. 11.
    Ata A, Gurses I, Kiykim A, et al. Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer. Am J Case Rep. 2012;13:268–70.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Usui J, Yokoyama C, Hagiwara M, et al. The detection of urinary podocytes from drug-induced glomerular thrombotic microangiopathy in advanced cancer patients. Clin Lab. 2016;62:2413–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Brocklebank V, Wood K, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2017; in press.Google Scholar
  14. 14.
    Katagiri D, Hamasaki Y, Doi K, et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol. 2013;24:2034–43.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Katagiri D, Hamasaki Y, Doi K, et al. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney Int. 2015;89:374–85.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  1. 1.Division of Nephrology and HypertensionVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of NephrologyNational Center for Global Health and MedicineTokyoJapan

Personalised recommendations